IMKELDI vs IRESSA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. IMKELDI and IRESSA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMKELDI	IRESSA
Rating	New	70/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	GEFITINIB
Manufacturer	Shorla Oncology	Astrazeneca
Dosage forms	Solution	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Non-Small-Cell Lung Carcinoma

imkeldi iressa

Rating

New

70/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

GEFITINIB

Manufacturer

Shorla Oncology

Astrazeneca

Dosage forms

Solution

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Imkeldi and Iressa?

Imkeldi contains Imatinib Mesylate, while Iressa contains Gefitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.